Short-course radiation plus immunotherapy and chemotherapy for rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Locally advanced rectal cancer (stage II or III) confirmed by biopsy, with the tumor within 10 cm of the anus
- No distant spread (metastasis) of cancer
- Good overall health (ECOG performance status 0–1: able to carry out normal activities)
- Adequate blood counts, kidney, and liver function
- No prior chemotherapy, radiation to the pelvis, or immunotherapy for this cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This Phase 2 trial studies whether adding sintilimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with locally advanced rectal cancer. It’s aimed at tumors with certain immune “signature” scores and specific cancer stage features.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a treatment for rectal cancer that combines chemotherapy and radiation over a longer period, along with an immunotherapy drug called camrelizumab. It aims to shrink the tumor and possibly preserve the anus for people with low-lying rectal cancer.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.